Medical Oncology, Journal Year: 2025, Volume and Issue: 42(5)
Published: April 4, 2025
Language: Английский
Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)
Published: Jan. 3, 2024
Abstract Breast cancer (BC) is a multifaceted disease characterized by distinct molecular subtypes and varying responses to treatment. In BC, the phosphatidylinositol 3-kinase (PI3K) pathway has emerged as crucial contributor development, advancement, resistance This review article explores implications of PI3K in predictive, preventive, personalized medicine for BC. It emphasizes identification predictive biomarkers, such PIK3CA mutations, utility profiling guiding treatment decisions. The also discusses potential targeting preventive strategies customization therapy based on tumor stage, subtypes, genetic alterations. Overcoming inhibitors exploring combination therapies are addressed important considerations. While this field holds promise improving patient outcomes, further research clinical trials needed validate these approaches translate them into practice. Graphical
Language: Английский
Citations
26
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: March 9, 2023
Breast cancer is one of the common malignancies with poor prognosis worldwide. The treatment breast patients includes surgery, radiation, hormone therapy, chemotherapy, targeted drug therapy and immunotherapy. In recent years, immunotherapy has potentiated survival certain patients; however, primary resistance or acquired attenuate therapeutic outcomes. Histone acetyltransferases induce histone acetylation on lysine residues, which can be reversed by deacetylases (HDACs). Dysregulation HDACs via mutation abnormal expression contributes to tumorigenesis tumor progression. Numerous HDAC inhibitors have been developed exhibited potent anti-tumor activity in a variety cancers, including cancer. ameliorated immunotherapeutic efficacy patients. this review, we discuss cancer, dacinostat, belinostat, abexinostat, mocetinotat, panobinostat, romidepsin, entinostat, vorinostat, pracinostat, tubastatin A, trichostatin tucidinostat. Moreover, uncover mechanisms improving Furthermore, highlight that might agents potentiate
Language: Английский
Citations
25
Pharmacological Research, Journal Year: 2024, Volume and Issue: 204, P. 107205 - 107205
Published: May 6, 2024
Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptors, progesterone receptors and lacks HER2 overexpression. This absence of critical molecular targets poses significant challenges for conventional therapies. Immunotherapy, remarkably immune checkpoint blockade, offers promise TNBC treatment, but its efficacy remains limited. Epigenetic dysregulation, including altered DNA methylation, histone modifications, imbalances in regulators such as BET proteins, plays a crucial role development resistance to treatment. Hypermethylation tumor suppressor gene promoters the imbalance methyltransferases EZH2 deacetylases (HDACs) profoundly influence cell proliferation, survival, metastasis. In addition, epigenetic alterations critically shape microenvironment (TME), composition, cytokine signaling, expression, ultimately contributing evasion. Targeting these mechanisms with specific inhibitors HDAC combination immunotherapy represents compelling strategy remodel TME, potentially overcoming evasion enhancing therapeutic outcomes TNBC. review aims comprehensively elucidate current understanding modulation TNBC, on potential combining therapies overcome posed by this subtype.
Language: Английский
Citations
16
Cancers, Journal Year: 2024, Volume and Issue: 16(11), P. 2094 - 2094
Published: May 31, 2024
Triple Negative Breast Cancer (TNBC) is characterized by distinct molecular subtypes with unique biological and clinical features. This systematic review aimed to identify articles examining the differences in tumor immune microenvironment (TIME) across different TNBC subtypes. Six studies meeting inclusion criteria were analyzed, utilizing gene expression profiling bioinformatic analyses classify samples into subtypes, as well immunohistochemistry cell deconvolution methods characterize TIME. Results revealed significant heterogeneity composition among immunomodulatory (IM) subtype demonstrating robust infiltration, composed mainly of adaptive cells along an increased density CTLA-4+ PD-1+ TILs, high PD-L1 expression, upregulation FOXP3+ Tregs. A more immunosuppressive TIME a predominance innate lower levels tumor-infiltrating lymphocytes (TILs) was observed luminal androgen receptor (LAR) tumors. In mesenchymal stem-like (MSL) tumors, cells, number M2 tumor-associated macrophages (TAMs), while BL M tumors displayed poor responses, indicating “immune-cold” phenotype. Differential activation signaling pathways, genomic diversity, metabolic reprogramming identified contributors heterogeneity. Understanding this interplay crucial for tailoring therapeutic strategies, especially regarding immunotherapy.
Language: Английский
Citations
13
Exploration, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 9, 2025
ABSTRACT The insufficient infiltration and functional inhibition of CD8 + T cells due to tumor microenvironment (TME) are considered enormous obstacles anti‐tumor immunotherapy. Herein, a pH‐responsive core‐shell manganese phosphate nanomodulator co‐loading siPD‐L1 Mn 2+ into nanoparticles coated with hyaluronic acid was prepared, which aimed at the bidirectional reprogramming microenvironment: (1) “Brakes off,” restoring function by knockdowning PD‐L1 expression cells; (2) “Step on accelerator,” promoting in tumors tissue based multidimensional immune effects (immunogenic cell death induced enhancing cGAS‐STING pathway, proliferation maturation relative cells). Additionally, this strategy could induce macrophage polarization inhibit regulatory site. This work provided reprogram TME for an enhanced comprehensive effect triple negative breast cancer, offers robust method immunotherapy future clinical applications.
Language: Английский
Citations
1
Journal of Materials Chemistry B, Journal Year: 2023, Volume and Issue: 11(36), P. 8586 - 8604
Published: Jan. 1, 2023
Immunotherapy is a new type of tumor treatment. In this review, the main focus on an overview research progress immunotherapy in cancer treatment and combined application with other therapeutic approaches.
Language: Английский
Citations
19
Translational Breast Cancer Research, Journal Year: 2024, Volume and Issue: 5, P. 4 - 4
Published: Jan. 1, 2024
Abstract: Breast cancer (BC) is the most common neoplasm in women worldwide and one of leading causes female death. The triple-negative subtype, characterized by absence hormone receptor (HR) human epidermal growth factor 2 (HER2), tends to occur younger patients, be more aggressive less differentiated. Furthermore, this subtype considered immunogenic associated with higher levels tumor cell infiltration, mainly lymphocytes. Tumor-infiltrating lymphocytes (TILs) play a crucial role interaction host's immune system cells. microenvironment critical development progression. Assessment infiltrating can provide valuable information about response and, given lack biomarkers guide treatment decisions predict outcomes tumors as potential biomarker. Some evidence suggests that these are better responses systemic treatment, longer progression-free survival overall (OS). However, escalation or de-escalation strategies for BC (TNBC) currently do not consider presence density TILs therapeutic decisions. appear useful predictive prognostic indicators. Further clinical studies needed confirm relationships integrate biomarker consistently into practice. This article summarizes key concepts relating infiltrate BC, along current status future prospects regarding
Language: Английский
Citations
8
PLoS ONE, Journal Year: 2024, Volume and Issue: 19(1), P. e0297260 - e0297260
Published: Jan. 16, 2024
Background The triple negative breast cancer (TNBC) is the most malignant subtype of with high aggressiveness. Although paclitaxel-based chemotherapy scenario present mainstay in TNBC treatment, paclitaxel resistance still a striking obstacle for cure. So it imperative to probe new therapeutic targets through illustrating mechanisms underlying chemoresistance. Methods Single cell RNA sequencing (scRNA-seq) data cells treated at different points were downloaded from Gene Expression Omnibus (GEO) database. Seurat R package was used filter and integrate scRNA-seq expression matrix. Cells further clustered by FindClusters function, gene marker each subset defined FindAllMarkers function. Then, hallmark score calculated AUCell package, biological function highly expressed interest genes analyzed DAVID Subsequently, we performed pseudotime analysis explore change patterns drug SCENIC identify key transcription factors (TFs). Finally, inhibitors which also CTD Results We finally obtained 6 subsets 2798 cells, marked as AKR1C3+, WNT7A+, FAM72B+, RERG+, IDO1+ HEY1+HCC1143 subsets, among HEY1+ proportions increased increasing treatment time, then regarded subsets. Hallmark showed that these associated inflammatory response, virus interferon response activation. In addition, regulatory networks (GRNs) indicated 3 TFs (STAT1, CEBPB IRF7) played vital role promoting development, five common targeted potential combination therapies identified. Conclusion this study, identified relevant IFs their inhibitors, offers essential molecular basis beneficial guidance clinical therapy.
Language: Английский
Citations
7
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: July 9, 2024
Macrophages represent an immune cell population characterized by high plasticity and a range of properties functions. Their activation status specific phenotype are highly associated with their localization the environmental cues they receive. The roles macrophages in cancer development diverse. Despite antitumor effects at early stages disease, presence tumor microenvironment (TME) has been linked to promotion upon disease establishment. Tumor (TAMs) key components breast TME have poor clinical outcomes. High TAM densities were found correlate progression, increased metastatic potential prognosis. Interestingly, considerably higher levels TAMs patients triple negative (TNBC)—the most aggressive type cancer—compared other types. present review summarizes recent findings regarding distinct subsets involvement progression metastasis. It highlights constant interplay between cells its major contribution including such aspects as, polarization toward promoting phenotype, induction epithelial mesenchymal transition (EMT) enhancement stem properties. Further, we discuss relevance these findings, focusing on how better delineation metastasis will facilitate selection more efficient treatment options.
Language: Английский
Citations
7
Journal of Cancer, Journal Year: 2023, Volume and Issue: 14(5), P. 850 - 873
Published: Jan. 1, 2023
Programmed death-1 is a protein found on the surface of immune cells that can interact with its ligand, programmed death-ligand 1 (PD-L1), which expressed plasma membrane, secreted cellular exosomes, in cell nuclei, or as circulating soluble protein. This interaction lead to escape cancer patients. In clinical settings, PD-L1 plays an important role tumor disease diagnosis, determining therapeutic effectiveness, and predicting patient prognosis. inhibitors are also essential components immunotherapy. Thus, detection levels crucial, especially era precision therapy. recent years, innovations have been made traditional immunoassay methods development new immunoassays for detection. review aims summarize research progress technology highlight applications PD-L1.
Language: Английский
Citations
16